Top Story Today
The FDA's New Shortcut for Ultra-Rare Gene Therapies Changes Everything
A new FDA draft guidance would let ultra-rare gene therapies win approval without traditional large-scale clinical trials. Under the "plausible mechanism framework," sponsors who can prove their therapy hits the right genetic target with rock-solid biology could run single-arm studies with as few as a handful of patients. One platform trial could cover multiple mutations at once, instead of requiring separate trials for each. For developers spending $10 to $50 million on programs serving fewer than 20 patients, this could be the difference between a viable program and an abandoned one.
Why it matters: Only 5% of rare diseases have any approved treatment. By formally acknowledging that you can't evaluate a therapy for 12 patients the same way you evaluate one for 12 million, the FDA may have just unlocked an entire generation of cures that were scientifically possible but economically impossible.
Read more →Regulatory Rumblings
The FDA's Golden Tickets Have an Authority Problem
FDA staff are raising alarms about who actually has the legal authority to approve drugs under the Priority Review Voucher system. Vouchers now sell for up to $200 million, and 85% of biotech executives say PRV potential materially influenced their decision to pursue rare disease programs. The confusion comes as CDER has burned through four acting directors since early 2025 and lost nearly 500 employees in a single fiscal year.
Read more →Deals & M&A
Regeneron Crashes the Radiopharma Party With a $4.3 Billion Alliance
Big pharma has collectively spent over $10 billion on radioligand therapy deals in two years, and Regeneron just joined the frenzy. Its partnership with Australia's Telix Pharmaceuticals could be worth up to $4.3 billion across eight oncology programs, though the actual upfront is just $40 million. The deal pairs Regeneron's antibody engineering with Telix's radiolabeling expertise, confirming that every major oncology player now considers nuclear-powered cancer drugs essential.
Read more →Lilly Drops $202 Million on a Startup Trying to Make Viral Vectors Obsolete
Eli Lilly acquired Engage Biologics, a seed-stage company with zero human data and a non-viral gene delivery platform called Tethosome. The technology packages therapeutic DNA inside lipid nanoparticles (the same fatty bubbles behind mRNA Covid vaccines) and claims 100-fold greater gene expression than standard approaches. It's the latest move in Lilly's genetic medicine shopping spree, which now includes a growing share of its pipeline.
Read more →Funding & Financings
$290 Million for a Migraine Drug Nobody's Tested in Humans Yet
Paragon Therapeutics spinout Mentari is going public via reverse merger at a $421 million valuation, backed by $290 million from a16z, Blackstone, Wellington, and others. Its bet: a protein called PACAP triggers migraines through a pathway that blockbuster CGRP drugs don't touch. With 40 to 50% of CGRP patients still not getting adequate relief, Mentari sees a massive gap. First human data is expected in 2027.
Read more →